Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT04425824 Not yet recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Start date: June 15, 2020
Phase: Phase 2
Study type: Interventional

Exploring the efficacy and safety of Toripalimab with Rituximab for treatment of relapsed refractory CD20 positive diffuse large B-cell lymphoma.

NCT ID: NCT04425421 Recruiting - Burkitt Lymphoma Clinical Trials

Recommendations for the Treatment of Children With Burkitt's Lymphoma

GFALMB2019
Start date: November 1, 2020
Phase:
Study type: Observational

This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.

NCT ID: NCT04425070 Active, not recruiting - Clinical trials for Peripheral T-cell Lymphoma

A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma

TOUCH
Start date: August 18, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is proposed with treatment of ATG-010 combined with chemotherapy regimens which will be chosen by investigators (ICE [ifosfamide+carboplatin+etoposide] or GEMOX [gemcitabine+oxaliplatin] or Tislelizumab), after treatments of 2 to 6 cycles transferring to ATG-010 monotherapy maintenance treatment, to evaluate the safety, tolerability, and primary efficacy of ATG-010 in R/R PTCL and NK/T-cell lymphoma patients.

NCT ID: NCT04423848 Terminated - Lymphoma Clinical Trials

Home Hospital for Lymphoma

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

The goal of this research is to evaluate an intervention, which the investigators call "Home Hospital for Lymphoma," that involves remote patient monitoring and home-based supportive care for patients hospitalized with lymphoma at Massachusetts General Hospital.

NCT ID: NCT04423549 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma

Start date: June 2020
Phase:
Study type: Observational

The purpose of this study is to determine the predictive value of a mRNA signature and liquid biopsy in patients with Diffuse Large B cell lymphoma.

NCT ID: NCT04423536 Recruiting - Clinical trials for Natural Killer T-cell Lymphoma

Predictive Value of a SNP Signature and Liquid Biopsy in Natural Killer T-cell Lymphoma

Start date: March 9, 2021
Phase:
Study type: Observational

The purpose of this study is to determine the Predictive value of a SNP signature and liquid biopsy in patients with natural killer T-cell lymphoma.

NCT ID: NCT04421560 Recruiting - Clinical trials for Primary Central Nervous System Lymphoma

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Start date: August 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL). The three drugs being used in the study are: - Pembrolizumab (MK3475) - Ibrutinib - Rituximab (or biosimilar)

NCT ID: NCT04419909 Not yet recruiting - Lymphoma, B-Cell Clinical Trials

Retreatment With CTL019/CTL119

Start date: May 2024
Phase: Phase 1
Study type: Interventional

This research study is designed to evaluate the effects of retreatment with CTL019/CTL119 in patients with late relapse of B-cell lymphomas.

NCT ID: NCT04419441 Recruiting - Hodgkin Lymphoma Clinical Trials

Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma

ICI-RT-1
Start date: June 24, 2020
Phase:
Study type: Observational

This is an observational retrospective study to investigate the efficacy and safety of the treatment with an immune checkpoint inhibitor (nivolumab or pembrolizumab) in combination with radiotherapy in patients with relapsed/refractory classical Hodgkin lymphoma.

NCT ID: NCT04419389 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)

R/R
Start date: March 2, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Study to determine the preliminary safety, tolerability, and pharmacokinetic (PK) profile of APR-246 in combination with either acalabrutinib or venetoclax + rituximab therapy in subjects with NHL, including relapsed and/or refractory (R/R) CLL and R/R MCL.